PharmaEssentia Corporation (TPE:6446)
Taiwan · Delayed Price · Currency is TWD | Market Cap | 495.25B +141.7% |
| Revenue (ttm) | 20.75B +64.2% |
| Net Income | 7.63B +88.3% |
| EPS | 18.50 +88.0% |
| Shares Out | 414.43M |
| PE Ratio | 64.60 |
| Forward PE | 37.87 |
| Dividend | 1.35 (0.11%) |
| Ex-Dividend Date | Jul 9, 2026 |
| Volume | 1,834,611 |
| Open | 1,205.00 |
| Previous Close | 1,205.00 |
| Day's Range | 1,190.00 - 1,235.00 |
| 52-Week Range | 407.92 - 1,645.00 |
| Beta | 0.65 |
| Analysts | Buy |
| Price Target | 1,482.61 (+24.07%) |
| Est. Earnings | Nov 9, 2026 |
About PharmaEssentia
PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and imm... [Read more]
Full Company ProfileFinancial Performance
In 2025, PharmaEssentia's revenue was 15.63 billion, an increase of 60.61% compared to the previous year's 9.73 billion. Earnings were 5.05 billion, an increase of 70.13%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for 6446 stock is "Buy." The 12-month stock price target is $1,483, which is an increase of 24.07% from the latest price.
News
PharmaEssentia Slides: Q2 2026
PharmaEssentia has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 12, 2026.
PharmaEssentia Quarterly report: Q2 2026
PharmaEssentia has published its Q2 2026 quarterly earnings report on August 12, 2026.
PharmaEssentia Quarterly report: Q1 2026
PharmaEssentia has published its Q1 2026 quarterly earnings report on May 13, 2026.
PharmaEssentia Quarterly report: Q4 2025
PharmaEssentia has published its Q4 2025 quarterly earnings report on March 26, 2026.
PharmaEssentia Says FDA Accepts SBLA For ET Treatment Ropeginterferon Alfa-2b-njft
(RTTNews) - PharmaEssentia USA Corp., a subsidiary of PharmaEssentia Corp. (6446.TW), on Tuesday said the U.S. Food and Drug Administration has accepted its supplemental Biologics License Application ...
PharmaEssentia Quarterly report: Q3 2025
PharmaEssentia has published its Q3 2025 quarterly earnings report on November 30, 2025.
ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b)
Today, a tribunal under the auspices of the International Chamber of Commerce (ICC) served a partial final award in a dispute between PharmaEssentia Corp. ("PharmaEssentia") and AOP Orphan Pharmaceuti...